PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

• J. C. Barrientos,
• P. M. Barr,
• A. R. Mato,
• C. S. Tam,
• P. Ghia,
• C. Moreno,
• N. E. Kay,
• T. Siddiqi,
• E. Szafer-Glusman,
• C. Zhou,
• L. Neumayr,
• G. Krigsfeld,
• W. G. Wierda,
• T. Shanafelt

Affiliations

J. C. Barrientos

1 Zucker School of Medicine at Hofstra/Northwell CLL Research & Treatment Program, Lake Success, NY

P. M. Barr

2 Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY

A. R. Mato

3 Memorial Sloan Kettering Cancer Center, New York, NY, United States of America

C. S. Tam

4 Peter MacCallum Cancer Center & St. Vincent’s Hospital and the University of Melbourne, Melbourne, VIC, Australia

P. Ghia

5 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

C. Moreno

6 Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

N. E. Kay

7 Mayo Clinic, Rochester, MN

T. Siddiqi

8 City of Hope National Medical Center, Duarte, CA

E. Szafer-Glusman

9 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA

C. Zhou

9 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA

L. Neumayr

9 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA

G. Krigsfeld

9 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA

W. G. Wierda

10 Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX

T. Shanafelt

11 Stanford University Medical Center, Stanford, CA, United States of America